144 related articles for article (PubMed ID: 25834463)
1. IncobotulinumtoxinA use in aesthetic indications in daily practice: a European multicenter, noninterventional, retrospective study.
Pavicic T; Prager W; Klöppel M; Ravichandran S; Galatoire O
Clin Cosmet Investig Dermatol; 2015; 8():135-42. PubMed ID: 25834463
[TBL] [Abstract][Full Text] [Related]
2. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.
Carruthers A; Carruthers J; Coleman WP; Donofrio L; Flynn T; Gold M; Heinz M; Harrington L; Jones D; McDaniel D; Rohrer T; Schlöbe A; Solish N; Weiss RA
Dermatol Surg; 2013 Apr; 39(4):551-8. PubMed ID: 23379292
[TBL] [Abstract][Full Text] [Related]
3. Safety of IncobotulinumtoxinA in the Treatment of Facial Lines: Results From a Pooled Analysis of Randomized, Prospective, Controlled Clinical Studies.
Coleman WP; Sattler G; Weissenberger P; Hast MA; Hanschmann A
Dermatol Surg; 2017 Dec; 43 Suppl 3():S293-S303. PubMed ID: 33065955
[TBL] [Abstract][Full Text] [Related]
4. Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines.
Prager W
Clin Pharmacol; 2013; 5():39-52. PubMed ID: 23516136
[TBL] [Abstract][Full Text] [Related]
5. Safety, Tolerability, and Efficacy of Repeat-Dose Injections of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results from a Prospective, Open-Label, Phase III Study.
Fischer T; Sattler G; Prager W; Rzany B; Pavicic T; Gauglitz G; Weissenberger P; Riaz S
J Drugs Dermatol; 2020 May; 19(5):461-469. PubMed ID: 32484631
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Lateral Periorbital Lines with Different Dilutions of IncobotulinumtoxinA.
Muti GF; Basso M
J Clin Aesthet Dermatol; 2017 Sep; 10(9):27-29. PubMed ID: 29344324
[No Abstract] [Full Text] [Related]
7. Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results From a Randomized, Double-Blind, Placebo-Controlled, Phase III Study.
Kerscher M; Rzany B; Prager W; Turnbull C; Trevidic P; Inglefield C
Dermatol Surg; 2015 Oct; 41(10):1149-57. PubMed ID: 26359996
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Tolerability of IncobotulinumtoxinA for Treating Glabellar Frown Lines in Korean Adults: A Postmarketing Observational Study.
Park JY; Sung NK; Pitt JM
Dermatol Surg; 2017 Dec; 43 Suppl 3():S304-S311. PubMed ID: 28961638
[TBL] [Abstract][Full Text] [Related]
9. Long-term results for incobotulinumtoxinA in the treatment of glabellar frown lines.
Rzany B; Flynn TC; Schlöbe A; Heinz M; Harrington L
Dermatol Surg; 2013 Jan; 39(1 Pt 1):95-103. PubMed ID: 23190342
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Double-Blind Trial to Investigate the Equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for Glabellar Frown Lines.
Kane MA; Gold MH; Coleman WP; Jones DH; Tanghetti EA; Alster TS; Rohrer TE; Burgess CM; Shamban AT; Finn E
Dermatol Surg; 2015 Nov; 41(11):1310-9. PubMed ID: 26509943
[TBL] [Abstract][Full Text] [Related]
11. IncobotulinumtoxinA in esthetics.
Kerscher M; Yutskovskaya Y; Flynn TC
J Drugs Dermatol; 2013 Jun; 12(6):e111-20. PubMed ID: 23839200
[TBL] [Abstract][Full Text] [Related]
12. IncobotulinumtoxinA for the Treatment of Glabellar Frown Lines: A Prospective, Multicenter, Single-arm Study in Taiwan.
Chao YY; Tseng FW; Yang YL; Chen YH; Hsu NJ; Chang LY
J Clin Aesthet Dermatol; 2019 Dec; 12(12):E53-E57. PubMed ID: 32038766
[No Abstract] [Full Text] [Related]
13. IncobotulinumtoxinA Is an Effective and Well-Tolerated Treatment for Upper Facial Lines: Results From an Open-Label Extension Period of a Phase III Study.
Trevidic P; Connolly SA; Biwer B; Ellers-Lenz B; Harrington LS; Kestemont P; Noah EM; Sattler G; Weissenberger P; Kerscher M
Dermatol Surg; 2017 Dec; 43 Suppl 3():S285-S292. PubMed ID: 33065954
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of IncobotulinumtoxinA for the treatment of platysmal bands of the aging neck: an open-label, prospective pilot study.
Gubanova EI; Panova OS; Sanchez EA; Rodina MY; Starovatova PA
J Drugs Dermatol; 2013 Dec; 12(12):1461-6. PubMed ID: 24301249
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the Efficacy and Durability of IncobotulinumtoxinA in the Treatment of the Upper Face in Adult Women.
de Almeida AT; de Sanctis Pecora C; Marques ER; Contin L; de Almeida CT; da Cunha AL
Dermatol Ther (Heidelb); 2024 Jul; ():. PubMed ID: 38954382
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the Effect of Incobotulinumtoxin A for Glabellar, Forehead, and Crow's Feet Lines Using A High Dilution.
Barbarino SC; van Loghem JAJ; Burgess CM; Corduff N
J Clin Aesthet Dermatol; 2021 Aug; 14(8):34-40. PubMed ID: 34840655
[TBL] [Abstract][Full Text] [Related]
17. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
Prager W; Rappl T
J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
[TBL] [Abstract][Full Text] [Related]
18. IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines.
Kerscher M; Fabi S; Fischer T; Gold M; Joseph J; Prager W; Rzany B; Yoelin S; Roll S; Klein G; Maas C
J Drugs Dermatol; 2021 Oct; 20(10):1052-1060. PubMed ID: 34636520
[TBL] [Abstract][Full Text] [Related]
19. IncobotulinumtoxinA for Glabellar Frown Lines in Chinese Subjects: A Randomized, Double-blind, Active-Controlled Phase-3 Study.
Wu Y; Roll S; Klein G; Geister TL; Makara MA; Li B
Plast Reconstr Surg Glob Open; 2023 May; 11(5):e4956. PubMed ID: 37250827
[TBL] [Abstract][Full Text] [Related]
20. A Phase III Study of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines.
Imhof M; Kühne U
J Clin Aesthet Dermatol; 2011 Oct; 4(10):28-34. PubMed ID: 22010053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
